In our retrospective analyses of human breast tumors with BRCA1/2 or PALB2 mutations from patients, we observed a strong association between FLT1 activation in human tumor cells at pre-treatment and subsequent development of PARPi resistance. Here, PALB2 is linked to breast neoplasm.